parallel FDA [Design Issues]

posted by jag009  – NJ, 2013-04-05 23:10 (4405 d 05:19 ago) – Posting: # 10363
Views: 7,784

Hi Detlew,

❝ Dear Helmut, dear John,


❝ ❝ ❝ Question, the anova model (GLM) will only contain 1 factor, correct?

❝ ❝

❝ ❝ Yep – I would suggest treatment. :-D


❝ A one-way ANOVA (GLM) evaluation will not fit the FDA guideline (see this post long ago).

❝ It is equivalent to the assumption of equal variances.


❝ If you only have 2 groups you can revert to the Welch t-test.

❝ Or you must code something with Proc MIXED (if you speak SASenese :cool:)


Something like this? :-D

Proc mixed data=s1;
class subject trt;
model lcmax=trt / ddfm=satterth;
lsmeans trt /pdiff cl alpha=.1;
estimate 'T vs R' trt 1 -1/ cl alpha=0.1;

John

Complete thread:

UA Flag
Activity
 Admin contact
23,424 posts in 4,927 threads, 1,669 registered users;
95 visitors (0 registered, 95 guests [including 8 identified bots]).
Forum time: 04:30 CEST (Europe/Vienna)

There are two possible outcomes: if the result confirms the
hypothesis, then you’ve made a measurement. If the result is
contrary to the hypothesis, then you’ve made a discovery.    Enrico Fermi

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5